Pharmaceutical company Abbott partners with health tech companies for diabetes care


Pharmaceutical company Abbott said on Tuesday that it has partnered with various health technology companies such as BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care.

The company said it has also partnered with Health, Healthifyme and Fitterfly as part of the initiative.



Through these collaborations, Abbott aims to bring blood glucose monitoring solutions to 8 million people with diabetes, of which approximately 6.5 million users can access through PharmEasy and 1MG, the pharmaceutical company said in a statement.

The pharmaceutical company is working to enable personalized lifestyle and therapy interventions, so people with diabetes can achieve holistic blood sugar management goals, he added.

“Ongoing research and strategic partnerships have simplified and strengthened diabetes management over the years. New diabetes technology has paved the way for accurate and informed decision-making,” said Kalyan Sattaru, general manager of Abbott’s diabetes care business.

BeatO co-founder and CEO Gautam Chopra noted that using Abbott’s FreeStyle Libre with BeatO’s app ecosystem will provide its users with accurate data, as well as actionable insights to manage and control effectively blood sugar levels.

“We are continually striving to make diabetes management more effective and convenient for our members and this program is a step in the same direction,” he added.

Similarly, Sugar.fit co-founder and CEO Madan Somasundaram said the company’s mission is to empower people with chronic diseases to live better, healthier lives and reverse the chronic metabolic disorders.

Technology is combined with science and human coaching to help millions of Indians manage and reverse diabetes through a data-driven and highly consumer-centric digital health experience, he said. added.

India has the second highest diabetes population in the world.

Recent studies show that healthcare for non-communicable diseases has been disrupted in India, with up to 87% of people with diabetes reducing doctor visits due to the pandemic, and less than half having a home blood glucose meter.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

Comments are closed.